LABORATORIO REIG JOFRE (RJF) AI Stock Analysis

LABORATORIO REIG JOFRE

(BME:RJF)

Select Model

Rating:52Neutral

Price Target:EUR 3.00▲(14.94% Upside)

Action:reiterated

Date:08/06/26

The score is held up by acceptable financial fundamentals and a stable balance sheet, but it is reduced by weak 2025 cash flow, the recent revenue and earnings decline, and a rich valuation. Technicals are only mildly supportive, so they do not materially offset the fundamental drag.

Positive Factors

Business model diversificationA dual revenue model (branded/specialty medicines plus CDMO services) provides structural balance: product sales drive margin upside while contract manufacturing supplies recurring fee-based revenue and capacity utilization, reducing single-source demand risk and supporting steady cash flow over cycles.

Negative Factors

Sharp 2025 revenue & margin hitA large year-on-year revenue decline and collapse in operating margins materially undermine sustainable earnings power. Such deterioration reduces retained earnings available for reinvestment and makes achieving prior returns difficult without clear signs of demand recovery or cost restructuring.

LABORATORIO REIG JOFRE (RJF) vs. iShares MSCI Spain ETF (EWP)

Market Cap: EUR 212.43M
Dividend Yield: 0.74%
Average Volume (3M): 8,274
Price to Earnings (P/E): 30.8
Beta (1Y): 0.37
Revenue Growth: -0.42%
EPS Growth: 4.56%
Country: Spain
Employees: 1,512
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

LABORATORIO REIG JOFRE Business Overview & Revenue Model

Company Description

Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs,...

How the Company Makes Money

RJF primarily makes money through (1) selling pharmaceutical products and healthcare items and (2) providing contract development and manufacturing services. Product-related revenue is generated from the commercialization of its own portfolio (includ...

LABORATORIO REIG JOFRE Financial Statement Overview

Summary

Multi-year revenue growth, positive profitability, and a reasonably strong balance sheet support the score, but the sharp 2025 drop in revenue, earnings, and free cash flow meaningfully weakens the profile.

Income Statement

54Neutral

Balance Sheet

72Positive

Cash Flow

38Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	332.15M	331.10M	338.89M	316.09M	271.15M	236.23M
Gross Profit	136.35M	81.71M	195.68M	176.89M	69.58M	144.98M
EBITDA	34.28M	30.48M	36.18M	33.89M	30.44M	24.66M
Net Income	6.89M	5.02M	10.38M	9.41M	8.11M	5.09M
Balance Sheet
Total Assets	420.70M	396.56M	344.85M	330.55M	321.19M	324.98M
Cash, Cash Equivalents and Short-Term Investments	14.78M	16.84M	16.08M	6.36M	6.88M	5.16M
Total Debt	119.58M	98.53M	58.52M	53.49M	61.24M	67.38M
Total Liabilities	197.21M	170.24M	130.90M	126.29M	126.64M	136.46M
Stockholders Equity	221.11M	218.07M	213.97M	204.35M	194.63M	188.59M
Cash Flow
Free Cash Flow	0	-13.78M	10.56M	6.34M	4.75M	-5.26M
Operating Cash Flow	0	1.51M	31.34M	19.11M	16.15M	14.50M
Investing Cash Flow	0	-17.82M	-31.96M	-12.88M	-12.72M	-34.70M
Financing Cash Flow	0	16.31M	5.59M	-7.16M	-2.04M	13.67M

LABORATORIO REIG JOFRE Technical Analysis

Technical Analysis SentimentNeutral

Last Price2.61

Price Trends

50DMA2.62Negative

100DMA2.65Negative

200DMA2.63Negative

Market Momentum

MACD-0.01Negative

RSI52.63Neutral

STOCH66.11Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:RJF, the sentiment is Neutral. The current price of 2.61 is above the 20-day moving average (MA) of 2.60, below the 50-day MA of 2.62, and below the 200-day MA of 2.63, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 52.63 is Neutral, neither overbought nor oversold. The STOCH value of 66.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:RJF.

LABORATORIO REIG JOFRE Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

ES:RJF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ES:CBAV	85Outperform	EUR 867.34M	19.07	41.91%	2.95%	10.89%	17.12%
ES:ROVI	78Outperform	EUR 3.16B	17.49	27.84%	1.52%	3.21%	39.34%
ES:ALM	65Neutral	EUR 2.31B	32.42	4.78%	1.71%	9.67%	174.00%
ES:FAE	61Neutral	EUR 1.50B	11.09	18.19%	2.66%	31.88%	-20.09%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ES:GRF	55Neutral	EUR 6.52B	16.42	8.43%	0.75%	-0.33%	51.93%
ES:RJF	52Neutral	EUR 212.43M	30.81	3.14%	0.74%	-0.42%	4.56%

* General Sector Average

Performance Comparison

ES:RJF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ES:RJF	LABORATORIO REIG JOFRE	2.61	-0.18	-6.42%
ES:ALM	Almirall SA	10.74	-1.28	-10.66%
ES:CBAV	Clinica Baviera	53.20	12.09	29.42%
ES:FAE	Faes Farma	4.82	0.45	10.22%
ES:GRF	Grifols (0RDU)	11.00	-0.02	-0.20%
ES:ROVI	Laboratorios Farmaceuticos Rovi	63.30	5.22	8.98%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 06, 2026

LABORATORIO REIG JOFRE AI Stock Analysis